psychedelics-investing Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap's Mental Health Technology
psychedelics-investing Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange
psychedelics-investing Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland
psychedelics-investing Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer
psychedelics-investing Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia
psychedelics-investing Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials
psychedelics-investing Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials
psychedelics-investing Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics
psychedelics-investing Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms
Pinnacle Hires San Diego Torrey Hills Capital for Investor Relations and Grants Incentive Stock Options
